Loading clinical trials...
Loading clinical trials...
A Study of the Effect of Conversion to Enteric-Coated Mycophenolate Sodium (EC-MPS) on Quality of Life in Patients With Gastrointestinal (GI) Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation (MYQOL)
Conditions
Interventions
Enteric-Coated Mycophenolate Sodium (EC-MPS)
Mycophenolate Mofetil (MMF)
Locations
1
United Kingdom
Novartis Investigative Site
Nottingham, United Kingdom
Start Date
September 1, 2005
Primary Completion Date
March 1, 2008
Last Updated
March 30, 2017
NCT07294183
NCT07090512
NCT05086003
NCT07392996
NCT03719339
NCT03726307
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions